BioCentury | Mar 3, 2021
Product Development

Vir looking ahead to other COVID settings after value-destroying miss in hospitalized patients

Vir and GSK are looking ahead to an imminent readout for their mAb to treat high-risk COVID-19 outpatients after a DSMB recommended the closure of a study arm evaluating the therapy in hospitalized patients. Vir...
BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

Led by Sean Nolan as executive chairman and Joe Nolan as CEO, the former management team of AveXis partnered with Deerfield Management to launch Jaguar Gene Therapy LLC. Jaguar’s preclinical pipeline of AAV9-based gene therapies...
BioCentury | Feb 23, 2021
Management Tracks

Kite’s Takeshita to head R&D for Daiichi Sankyo; plus TScan adds CFO Silver, Hahn joins Blackfynn’s board and moves at Intercept, Kira, Insilico, BioXcel and Re-Vana

Kite Pharma veteran Ken Takeshita will join Daiichi Sankyo Co. Ltd. (Tokyo:4568) as global head of R&D, succeeding Junichi Koga, who is retiring after more than a dozen years at the Japanese pharma. Kite, a unit of Gilead...
BioCentury | Feb 20, 2021
Product Development

BMS turns to mechanistic diversity in early oncology pipeline

As BMS builds out its early pipeline to find its next big act in cancer and head off revenue losses from upcoming patent cliffs, it’s taking a broad sweep across oncology’s hottest target spaces...
BioCentury | Feb 19, 2021
Deals

Rigel’s decision tree behind its RIPK1 Lilly deal

Rigel’s deal with Lilly for its clinical RIPK1 program will triple the biotech’s cash balance as it seeks to expand the label of its sole marketed product while also developing a wholly owned, earlier-stage clinical...
BioCentury | Feb 13, 2021
Finance

Qiming readies to kick off Chinese New Year with a first for Hong Kong exchange

After Qiming closed its sixth RMB fund in late January, Managing Partner Nisa Leung is looking ahead to her firm’s second public listing this year, one that she believes could clear a path for...
BioCentury | Feb 9, 2021
Finance

Sana leapfrogs Moderna for biggest pure-play biotech IPO yet: Data Byte

With Sana’s underwriters exercising their option to buy more shares in its IPO, the company has closed the offering at $675.6 million, leapfrogging Moderna’s 2018 offering to become the largest yet by a pure-play biotech....
BioCentury | Feb 5, 2021
Emerging Company Profile

Deals with Allogene, ADC reflect Overland’s ambition to tap parent Hillhouse’s network to bring innovation to China

Backed by Hillhouse’s deep pockets, Overland aims to leverage its parent firm’s biopharma ecosystem in China to bring first-in-class and best-in-class Western therapies to the country. Overland Pharmaceuticals launched...
BioCentury | Feb 4, 2021
Deals

Jazz strikes another chord in neuroscience via $7.2B GW pickup

With the acquisition of cannabinoid therapeutics company GW in Jazz’s largest deal ever, the company added a product and pipeline that complements its historical strength in neuroscience rather than oncology, where it has sought to...
BioCentury | Feb 4, 2021
Finance

Muted reception for Sensei, Landos on NASDAQ as more biotechs set to leap into public markets

While Sana’s massive IPO drew most of the attention among new listings Thursday, biotechs Sensei and Landos made quieter NASDAQ debuts, with several more companies set to price for Friday’s session. Sensei Biotherapeutics Inc. (NASDAQ:SNSE)...
Items per page:
1 - 10 of 2477
BioCentury | Mar 3, 2021
Product Development

Vir looking ahead to other COVID settings after value-destroying miss in hospitalized patients

Vir and GSK are looking ahead to an imminent readout for their mAb to treat high-risk COVID-19 outpatients after a DSMB recommended the closure of a study arm evaluating the therapy in hospitalized patients. Vir...
BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

Led by Sean Nolan as executive chairman and Joe Nolan as CEO, the former management team of AveXis partnered with Deerfield Management to launch Jaguar Gene Therapy LLC. Jaguar’s preclinical pipeline of AAV9-based gene therapies...
BioCentury | Feb 23, 2021
Management Tracks

Kite’s Takeshita to head R&D for Daiichi Sankyo; plus TScan adds CFO Silver, Hahn joins Blackfynn’s board and moves at Intercept, Kira, Insilico, BioXcel and Re-Vana

Kite Pharma veteran Ken Takeshita will join Daiichi Sankyo Co. Ltd. (Tokyo:4568) as global head of R&D, succeeding Junichi Koga, who is retiring after more than a dozen years at the Japanese pharma. Kite, a unit of Gilead...
BioCentury | Feb 20, 2021
Product Development

BMS turns to mechanistic diversity in early oncology pipeline

As BMS builds out its early pipeline to find its next big act in cancer and head off revenue losses from upcoming patent cliffs, it’s taking a broad sweep across oncology’s hottest target spaces...
BioCentury | Feb 19, 2021
Deals

Rigel’s decision tree behind its RIPK1 Lilly deal

Rigel’s deal with Lilly for its clinical RIPK1 program will triple the biotech’s cash balance as it seeks to expand the label of its sole marketed product while also developing a wholly owned, earlier-stage clinical...
BioCentury | Feb 13, 2021
Finance

Qiming readies to kick off Chinese New Year with a first for Hong Kong exchange

After Qiming closed its sixth RMB fund in late January, Managing Partner Nisa Leung is looking ahead to her firm’s second public listing this year, one that she believes could clear a path for...
BioCentury | Feb 9, 2021
Finance

Sana leapfrogs Moderna for biggest pure-play biotech IPO yet: Data Byte

With Sana’s underwriters exercising their option to buy more shares in its IPO, the company has closed the offering at $675.6 million, leapfrogging Moderna’s 2018 offering to become the largest yet by a pure-play biotech....
BioCentury | Feb 5, 2021
Emerging Company Profile

Deals with Allogene, ADC reflect Overland’s ambition to tap parent Hillhouse’s network to bring innovation to China

Backed by Hillhouse’s deep pockets, Overland aims to leverage its parent firm’s biopharma ecosystem in China to bring first-in-class and best-in-class Western therapies to the country. Overland Pharmaceuticals launched...
BioCentury | Feb 4, 2021
Deals

Jazz strikes another chord in neuroscience via $7.2B GW pickup

With the acquisition of cannabinoid therapeutics company GW in Jazz’s largest deal ever, the company added a product and pipeline that complements its historical strength in neuroscience rather than oncology, where it has sought to...
BioCentury | Feb 4, 2021
Finance

Muted reception for Sensei, Landos on NASDAQ as more biotechs set to leap into public markets

While Sana’s massive IPO drew most of the attention among new listings Thursday, biotechs Sensei and Landos made quieter NASDAQ debuts, with several more companies set to price for Friday’s session. Sensei Biotherapeutics Inc. (NASDAQ:SNSE)...
Items per page:
1 - 10 of 2477